ChemoCentryx Inc (CCXI) : Bvf Incil reduced its stake in ChemoCentryx Inc by 1.44% during the most recent quarter end. The investment management company now holds a total of 8,064,019 shares of ChemoCentryx Inc which is valued at $64,915,353 after selling 118,033 shares in ChemoCentryx Inc , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.ChemoCentryx Inc makes up approximately 10.68% of Bvf Incil’s portfolio.
Other Hedge Funds, Including , Emerald Acquisition Ltd. reduced its stake in CCXI by selling 21,600 shares or 62.61% in the most recent quarter. The Hedge Fund company now holds 12,900 shares of CCXI which is valued at $102,168. Tower Research Capital (trc) added CCXI to its portfolio by purchasing 753 company shares during the most recent quarter which is valued at $5,060.
ChemoCentryx Inc opened for trading at $7.95 and hit $8 on the upside on Monday, eventually ending the session at $7.98, with a gain of 0.50% or 0.04 points. The heightened volatility saw the trading volume jump to 2,79,770 shares. Company has a market cap of $381 M.
ChemoCentryx Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering developing and commercializing orally-administered therapeutics to treat autoimmune diseases inflammatory disorders and cancer. It targets the chemoattractant system which is a network of molecules including chemokine ligands and their associated receptors as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. The Company’s product portfolio includes CCX140 CCX872 CCX168 Vercirnon (Traficet-EN or CCX282) and CCX507.